Urologic Health Announces $11 Million Seed Financing to Advance Non-Invasive Bladder Function Monitoring

Urologic Health Inc., a pioneering medical device company focused on non-invasive urodynamics, has successfully closed an $11 million seed financing round to advance the clinical validation and commercialization of its innovative niu™ System. The financing was led by an undisclosed strategic investor, with participation from Edge Medical Ventures, SHD Partners, and Longevity Venture Partners, among other healthcare-focused investors. This funding round, announced on May 14, 2026, is set to bolster Urologic Health's efforts in navigating the FDA regulatory pathway while preparing for initial market entry in the United States.

The niu™ System represents a significant advancement in bladder function assessment, offering catheter-free urodynamic testing that converts bladder activity into clinically meaningful diagnostic data. This innovation addresses a critical gap in the current diagnostic landscape, where traditional tools are often invasive and uncomfortable, leading many patients to defer necessary assessments. Urologic Health aims to transform the patient experience by providing a non-invasive alternative that supports routine, repeatable assessments and longitudinal monitoring of bladder function.

The funding will primarily support clinical validation efforts and the FDA 510(k) regulatory pathway, which is essential for bringing the niu™ System to market. Urologic Health has already completed early feasibility studies demonstrating the system's capability to capture clinically relevant bladder activity non-invasively. The company plans to use the new capital to further develop its product and manufacturing processes while establishing its headquarters in Jersey City, New Jersey, in preparation for its U.S. market entry.

The medical devices sector, particularly in urology, is witnessing a growing demand for innovative solutions that enhance patient care while minimizing discomfort. Conditions such as overactive bladder, urinary retention, incontinence, and benign prostatic hyperplasia (BPH) affect millions globally, and the need for effective diagnostic tools is more pressing than ever. Urologic Health's niu™ System not only addresses the limitations of current invasive diagnostic methods but also aligns with broader trends in healthcare that prioritize patient-centered care and technological advancements.

As Urologic Health Inc. moves forward with its clinical validation and regulatory efforts, the successful fundraising underscores the increasing interest and investment in non-invasive medical technologies. The outcome of this venture could have significant implications for the urology field, potentially leading to improved patient outcomes and a shift in how bladder function assessments are conducted. The company's innovative approach may pave the way for future advancements in medical device technology, reinforcing the importance of addressing patient needs through less invasive solutions.